TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24722493

Group type: EXPERIMENTAL
Intervention: Intensive therapy (INT)
Number of subjects: 1217

Group type: COMPARATOR
Intervention: Conventional therapy (CONV)
Number of subjects: 1217

Group type: EXPERIMENTAL
Intervention: Cheiroarthropathy presence
Number of subjects: 1217

Group type: EXPERIMENTAL
Intervention: DASH functional disability scores
Number of subjects: 1217
Study: 22398060

Group type: EXPERIMENTAL
Intervention: Once daily mesalazine (1×2 g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Twice daily mesalazine (2×1 g)
Number of subjects: 0
Study: 19931399

Group type: EXPERIMENTAL
Intervention: Unmedicated BD subjects
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Medicated BD subjects
Number of subjects: 35

Group type: COMPARATOR
Intervention: Healthy controls (matched to unmedicated BD subjects)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Healthy controls (matched to medicated BD subjects)
Number of subjects: 35
Study: 17081574

Group type: EXPERIMENTAL
Intervention: Intervention A (small breakfast, snack, and standard lunch)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Intervention B (standard breakfast, snack, and small lunch)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control (standard breakfast, no snack and standard lunch)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Mid-morning snack (part of both interventions A and B)
Number of subjects: 69
Study: 15740828

Group type: EXPERIMENTAL
Intervention: Intravenous pentazocine (0.5mg/kg)
Number of subjects: 88
Study: 12164994

Group type: EXPERIMENTAL
Intervention: Preventive occupational therapy (OT)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Active control (social activity group)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Passive control (nontreatment group)
Number of subjects: 163
Study: 10207539

Group type: EXPERIMENTAL
Intervention: Indinavir 800 mg three times a day
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Ritonavir 600 mg twice a day
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Ritonavir 400 mg twice a day and saquinavir 400 mg twice a day
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Indinavir (in antiretroviral drug-naive patients)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Ritonavir (in antiretroviral drug-naive patients)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Ritonavir + saquinavir (in antiretroviral drug-naive patients)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Indinavir (in drug-experienced patients)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Ritonavir (in drug-experienced patients)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Ritonavir + saquinavir (in drug-experienced patients)
Number of subjects: 284
Study: 9097805

Group type: EXPERIMENTAL
Intervention: Subconjunctival mitomycin C (0.5 mg/ml) applied for 1-, 3-, or 5-minutes
Number of subjects: 78

Group type: COMPARATOR
Intervention: No mitomycin C (Control)
Number of subjects: 78
Study: 2710266

Group type: EXPERIMENTAL
Intervention: Intravenous ranitidine 50 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oral ranitidine 150 mg
Number of subjects: 6
Study: 47944

Group type: EXPERIMENTAL
Intervention: C.F. antibodies (IgG)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: I.D. technique (IgM and/or low titres of IgG)
Number of subjects: 173
Study: 31941483

Group type: EXPERIMENTAL
Intervention: Intraarticular HADMSCs injection with LIPUS
Number of subjects: 96

Group type: COMPARATOR
Intervention: Intraarticular HADMSCs injection with sham LIPUS
Number of subjects: 96

Group type: COMPARATOR
Intervention: Normal saline with LIPUS
Number of subjects: 96
Study: 30224325

Group type: EXPERIMENTAL
Intervention: Late parenteral nutrition
Number of subjects: 1440

Group type: COMPARATOR
Intervention: Early parenteral nutrition
Number of subjects: 1440
Study: 28608756

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 478

Group type: COMPARATOR
Intervention: Guidelines-based asthma care
Number of subjects: 478
Study: 25707331

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Gonadotropins
Number of subjects: 900
Study: 23881774

Group type: EXPERIMENTAL
Intervention: Soy fiber (SF) biscuits (approximately 100 g/day) for 12 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control biscuits for 12 weeks
Number of subjects: 39
Study: 21441616

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg daily) for 30 and 90 days
Number of subjects: 59

Group type: COMPARATOR
Intervention: Phytohemagglutinin-stimulated T lymphocytes
Number of subjects: 59
Study: 19624576

Group type: EXPERIMENTAL
Intervention: Ibuprofen (10 mg/kg, maximum 400 mg)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Acetaminophen-codeine (1 mg/kg as codeine, maximum 60 mg)
Number of subjects: 66
Study: 17105953

Group type: EXPERIMENTAL
Intervention: GHB 40 mg/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GHB 50 mg/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GHB 60 mg/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GHB 72 mg/kg
Number of subjects: 8
Study: 15152747

Group type: EXPERIMENTAL
Intervention: Oral vitamin K antagonists (e.g., warfarin) for stroke prevention in AF
Number of subjects: 2300000
Study: 12100790

Group type: EXPERIMENTAL
Intervention: Computer Assisted Meal Related Insulin Therapy (CAMIT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Multiple Subcutaneous Injection (MSI)
Number of subjects: 50
Study: 9801184

Group type: EXPERIMENTAL
Intervention: Short-term chemoprophylaxis (minimum 14 days and 7 days without the onset of a case)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Long-term chemoprophylaxis (minimum 21 days and 7 days without the onset of a case)
Number of subjects: 700
Study: 9166489

Group type: EXPERIMENTAL
Intervention: 1-hour infusion of paclitaxel (135 mg/m2)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: 1-hour infusion of paclitaxel (200 mg/m2)
Number of subjects: 164

Group type: COMPARATOR
Intervention: 3-day divided dose schedule of paclitaxel (200 mg/m2)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: 1-day schedule of paclitaxel
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Both doses of paclitaxel (135 mg/m2 and 200 mg/m2)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: 200 mg/m2 dose of paclitaxel in non-small cell lung cancer
Number of subjects: 164
Study: 2515220

Group type: EXPERIMENTAL
Intervention: Corticosteroids (dexamethasone)
Number of subjects: 126
Study: 334211

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg once-daily
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg once-daily
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Atenolol 200 mg once-daily
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 31724239

Group type: EXPERIMENTAL
Intervention: Deproteinized bovine bone mineral (DBBM)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Deproteinized porcine bone mineral (DPBM)
Number of subjects: 100
Study: 31216226

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus concurrent bevacizumab (15 mg/kg, cycles 2 to 6)
Number of subjects: 1873

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus concurrent and maintenance bevacizumab (cycles 2 to 22)
Number of subjects: 1873

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus concurrent and maintenance bevacizumab (stage IV)
Number of subjects: 1873

Group type: COMPARATOR
Intervention: Chemotherapy control (n = 625)
Number of subjects: 1873

Group type: EXPERIMENTAL
Intervention: BRCA1/2 mutated carcinomas
Number of subjects: 1873

Group type: EXPERIMENTAL
Intervention: Non-BRCA1/2 HRR
Number of subjects: 1873
Study: 27895192

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment (including Ca++-channel blockers and diuretics)
Number of subjects: 4290

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 4290

Group type: EXPERIMENTAL
Intervention: Older age, female sex, higher average systolic blood pressure during follow-up, initial greater LV mass index
Number of subjects: 4290
Study: 25880685

Group type: EXPERIMENTAL
Intervention: Conventional therapy plus CMC 1% (n = 90)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Conventional therapy only (control group, n = 90)
Number of subjects: 180
Study: 23719685

Group type: EXPERIMENTAL
Intervention: 25 Gy applied in 5 fractions
Number of subjects: 207

Group type: COMPARATOR
Intervention: 50 Gy in 20 fractions
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: 25 Gy applied in 5 fractions (good-fair overall condition)
Number of subjects: 207

Group type: COMPARATOR
Intervention: 50 Gy in 20 fractions (good-fair overall condition)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: 25 Gy applied in 5 fractions (poor overall condition)
Number of subjects: 207

Group type: COMPARATOR
Intervention: 50 Gy in 20 fractions (poor overall condition)
Number of subjects: 207
Study: 21855746

Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control
Number of subjects: 112
Study: 19083208

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 35
Study: 17416480

Group type: EXPERIMENTAL
Intervention: IV cyclophosphamide (CYC)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide (CYC)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Initial serum creatinine > 150 μmol/L
Number of subjects: 37

Group type: COMPARATOR
Intervention: Initial serum creatinine ≤ 150 μmol/L
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Renal relapses
Number of subjects: 37

Group type: COMPARATOR
Intervention: Initial route of CYC administration
Number of subjects: 37
Study: 15543358

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy with 0.625 mg of equine conjugated estrogens and 2.5 mg of medroxyprogesterone
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 11167428

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 40
Study: 9590593

Group type: EXPERIMENTAL
Intervention: Topical ofloxacin 0.3% eyedrops (10 times)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Topical ofloxacin 0.3% eyedrops (6 times)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Oral ofloxacin (200 mg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intravenous ofloxacin (200 mg)
Number of subjects: 50
Study: 8158887

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 30982687

Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR) plus standard of care
Number of subjects: 99

Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR)
Number of subjects: 99
Study: 28216244

Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine (5 doses of 2.7 x 10^5 PfSPZ at days 0, 28, 56, 84, and 140)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Number of subjects: 93
Study: 25894892

Group type: EXPERIMENTAL
Intervention: β-Alanine (BA) supplementation (4.0-5.6 g day(-1))
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 27
Study: 24033753

Group type: EXPERIMENTAL
Intervention: Subcutaneous implantable cardioverter defibrillator (S-ICD)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Transvenous ICD
Number of subjects: 15
Study: 21860557

Group type: EXPERIMENTAL
Intervention: High-sodium DASH diet (HSD)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Low-sodium DASH diet (LSD)
Number of subjects: 101
Study: 18199476

Group type: COMPARATOR
Intervention: Control etch-and-rinse adhesive
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adper Prompt L-Pop
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clearfil S3 Bond
Number of subjects: 0
Study: 17087307

Group type: EXPERIMENTAL
Intervention: Autologous implantation of bone marrow-mononuclear cells (BM-MNCs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transplantation of bone marrow-derived or peripheral blood-derived endothelial progenitor cells (EPCs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cell transplantation therapy
Number of subjects: 0
Study: 14627786

Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg once weekly)
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg twice weekly)
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Etanercept (50 mg twice weekly)
Number of subjects: 652

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 652
Study: 10831972

Group type: EXPERIMENTAL
Intervention: Danazol 200 mg three times daily for 6 months
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate 3.75 mg depot every 28 days for 6 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal controls (no treatment)
Number of subjects: 20
Study: 9356085

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) 15 mg/kg before CPB, followed by infusion of 1 mg x kg(‐1) x h(‐1) for 5 h
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) 15 mg/kg after CPB, followed by infusion of 1 mg x kg(‐1) x h(‐1) for 5 h
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) 15 mg/kg before CPB
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) 15 mg/kg after CPB
Number of subjects: 90
Study: 8210561

Group type: EXPERIMENTAL
Intervention: Initial steroid pulses 500 mg x3 (n = 17)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low oral steroid treatment (n = 20)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide pulses (n = 13)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide (n = 3)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Plasma exchanges (used in 4 cases)
Number of subjects: 30
Study: 3820944

Group type: EXPERIMENTAL
Intervention: Intravenous deferoxamine, 40 mg/kg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Intraperitoneal deferoxamine
Number of subjects: 7

Group type: COMPARATOR
Intervention: Both intravenous and intraperitoneal deferoxamine
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Deferoxamine (both routes)
Number of subjects: 7
Study: 30238801

Group type: EXPERIMENTAL
Intervention: Higher dairy protein supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community-level nutrition behavior change education
Number of subjects: 0
Study: 25827493

Group type: EXPERIMENTAL
Intervention: Obese women
Number of subjects: 19

Group type: COMPARATOR
Intervention: Normal weight controls
Number of subjects: 19
Study: 24746177

Group type: EXPERIMENTAL
Intervention: Aprepitant add-on triple antiemetic therapy (with a 5-HT(3) receptor antagonist and dexamethasone)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Standard antiemetic therapy (5-HT(3) receptor antagonist and dexamethasone)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Aprepitant add-on therapy in patients taking carboplatin and pemetrexed
Number of subjects: 134

Group type: COMPARATOR
Intervention: Standard antiemetic therapy in patients taking carboplatin and pemetrexed
Number of subjects: 134
Study: 23236685

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) coated mini implant
Number of subjects: 14

Group type: COMPARATOR
Intervention: Plain mini implant (control)
Number of subjects: 14
Study: 20932397

Group type: EXPERIMENTAL
Intervention: 40% Fuji IXGP Liquid diluted with water
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 40% Fuji IXGP Liquid (GC America)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group (untreated surfaces)
Number of subjects: 6
Study: 18833900

Group type: EXPERIMENTAL
Intervention: Barrier methods of prevention; specific products not detailed; evidence examined in the article.
Number of subjects: 0
Study: 16202050

Group type: EXPERIMENTAL
Intervention: Phosphoric acid 36%
Number of subjects: 15

Group type: COMPARATOR
Intervention: Non-rinse conditioner (NRC)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Carbide bur
Number of subjects: 15

Group type: COMPARATOR
Intervention: Diamond bur
Number of subjects: 15
Study: 12375460

Group type: EXPERIMENTAL
Intervention: Experimental crowns with different emergence profiles (up to 40 degrees)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (contralateral tooth)
Number of subjects: 6
Study: 10206085

Group type: EXPERIMENTAL
Intervention: rosiglitazone 2 mg in the fasting state
Number of subjects: 12

Group type: COMPARATOR
Intervention: rosiglitazone 2 mg following a standard high-fat breakfast
Number of subjects: 12
Study: 7599049

Group type: EXPERIMENTAL
Intervention: Use of serum markers for therapeutic response assessment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional assessment methods (not specified)
Number of subjects: 0
Study: 2189368

Group type: EXPERIMENTAL
Intervention: Early diet
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Non-ventilated infants
Number of subjects: 777
Study: 157810

Group type: EXPERIMENTAL
Intervention: Intravenous tolbutamide
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Intravenous glibornuride
Number of subjects: 5
Study: 31977129

Group type: EXPERIMENTAL
Intervention: Vibrio isolates
Number of subjects: 1440

Group type: EXPERIMENTAL
Intervention: Antibiotic resistance
Number of subjects: 1440

Group type: EXPERIMENTAL
Intervention: Virulence genes
Number of subjects: 1440

Group type: EXPERIMENTAL
Intervention: Antibiotic-resistant genes
Number of subjects: 1440
Study: 31251102

Group type: EXPERIMENTAL
Intervention: Honokiol liposome injection (HKLI)
Number of subjects: 0
Study: 29089756

Group type: EXPERIMENTAL
Intervention: CNSVS (Central Nervous System Vital Signs) computerized cognitive test battery
Number of subjects: 220
Study: 26601092

Group type: EXPERIMENTAL
Intervention: Self-care education through eight sessions by cardiology resident (Group A)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Self-care education through four pamphlets (Group B)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Self-care education through eight short message services (SMS) (Group C)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Usual care without self-care management training (Group D)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Self-care education through eight sessions (Group A)
Number of subjects: 180
Study: 24479703

Group type: EXPERIMENTAL
Intervention: Naïve conditions (mean pain score 2.3 ± 1.0)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-naïve conditions (mean pain score 2.2 ± 1.4)
Number of subjects: 20
Study: 21078340

Group type: EXPERIMENTAL
Intervention: Smoking prevention program (3 lessons in 5th grade and 3 lessons in 6th grade)
Number of subjects: 3173

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 3173
Study: 19379611

Group type: EXPERIMENTAL
Intervention: Nasal saline irrigation
Number of subjects: 127

Group type: COMPARATOR
Intervention: Saline spray
Number of subjects: 127
Study: 18178988

Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg daily for 2 weeks, followed by flexible dose of 10 to 20 mg daily for 6 weeks
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 119
Study: 15349784

Group type: EXPERIMENTAL
Intervention: BCAA supplementation (12 g l(‐1) solution, 4 aliquots of 250 ml at 30 min intervals before exercise, additional 150 ml every 15 min during exercise)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (same volume and timing as BCAA)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: BCAA supplementation
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 11104347

Group type: EXPERIMENTAL
Intervention: Sodium valproate (VPA)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 9310273

Group type: EXPERIMENTAL
Intervention: Spirapril, 6 mg once daily
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Enalapril, 5-20 mg once daily
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study: 8339560

Group type: EXPERIMENTAL
Intervention: Cyclosporine 1% ophthalmic ointment
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 3554278

Group type: EXPERIMENTAL
Intervention: Combination of compression and O-(beta-hydroxyethyl)-rutosides
Number of subjects: 107

Group type: COMPARATOR
Intervention: Compression alone
Number of subjects: 107
Study: 30830164

Group type: EXPERIMENTAL
Intervention: Combination of clinical parameters + biomarkers (leptin + high molecular weight adiponectin + VEGF)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Clinical model
Number of subjects: 117
Study: 29802398

Group type: EXPERIMENTAL
Intervention: Moderate-to-severe OSA
Number of subjects: 1921

Group type: COMPARATOR
Intervention: No OSA
Number of subjects: 1921
Study: 26780387

Group type: EXPERIMENTAL
Intervention: Combination of lenalidomide (15 mg/kg), docetaxel (75 mg/m²), and prednisone (10 mg daily)
Number of subjects: 63
Study: 25280420

Group type: EXPERIMENTAL
Intervention: Saturated fatty acids (SFAs)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Stearic acid
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Palmitic acid
Number of subjects: 55
Study: 23258727

Group type: EXPERIMENTAL
Intervention: Assistance from a tutor
Number of subjects: 35

Group type: COMPARATOR
Intervention: Self-learning tutorial
Number of subjects: 35
Study: 21146655

Group type: EXPERIMENTAL
Intervention: 30 months of dual antiplatelet therapy (DAPT) with thienopyridine (clopidogrel or prasugrel) plus aspirin
Number of subjects: 20245

Group type: COMPARATOR
Intervention: 12 months of dual antiplatelet therapy (DAPT) with thienopyridine (clopidogrel or prasugrel) plus aspirin
Number of subjects: 20245

Group type: COMPARATOR
Intervention: Placebo plus aspirin after 12 months of open-label thienopyridine treatment
Number of subjects: 20245
Study: 17013969

Group type: EXPERIMENTAL
Intervention: FBCx
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 16301700

Group type: EXPERIMENTAL
Intervention: HAMD-7
Number of subjects: 410

Group type: COMPARATOR
Intervention: HAMD-17
Number of subjects: 410